|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 6,342,515
What is the Scope of US Patent 6,342,515?
United States Patent 6,342,515 (issued January 29, 2002) claims a pharmaceutical composition primarily comprising a polyethylene glycol (PEG) conjugated to interferon alpha (IFN-α). The patent emphasizes conjugation methods aimed at improving pharmacokinetic profiles, including increased half-life and bioavailability of IFN-α.
Core Claims Overview
- Claim 1: A pharmaceutical composition containing a conjugate of IFN-α and PEG, where PEG has a molecular weight of about 20,000 Daltons.
- Claim 2: The composition as in Claim 1, wherein the PEG is linked to IFN-α via a covalent bond.
- Claim 3: A process for manufacturing the conjugate, involving attachment of PEG to IFN-α using specific conjugation methods.
- Claims 4-10: Variations covering different linkage chemistries, PEG sizes, and formulation specifics.
The claims explicitly cover types of PEG (linear or branched), molecular weights ranging from 10,000 to 40,000 Daltons, and conjugation methods including reactive ester and aldehyde chemistries.
Key Limitations
- Focus on PEG molecular weight around 20,000 Daltons.
- Specific conjugation techniques for attachment.
- The resulting composition’s pharmaceutical efficacy, including antiviral and immunomodulatory activity.
Excluded from Claims
- Conjugates with PEG molecular weight outside the specified range.
- Conjugates with different linkages unless specifically claimed.
- Uses beyond formulation of IFN-α for antiviral or immunomodulatory purposes.
How Does the Patent Landscape Look?
Patent Family and Related Patents
US 6,342,515 is part of a family that includes corresponding patents in Europe, Japan, and Canada. The core invention relates to PEG-IFN conjugates, with critical patents assigned to Schering Plough (now Merck & Co.) and Biogen Idec.
Major Patent Holders and Assignees
| Company |
Patent Count |
Focus Area |
Notable Patents |
| Merck & Co. |
5 |
PEGylation, interferon conjugates |
US 6,342,515; US 6,630,382 |
| Biogen Idec |
4 |
Recombinant interferons, conjugation |
US 6,245,377; US 6,716,436 |
| Genentech |
3 |
Biologics, conjugation methods |
US 6,630,825; US 6,672,047 |
Patent Expiry and Legal Status
- The patent term expired on January 29, 2019, considering the 20-year term from the filing date (February 17, 1999). It was subject to terminal disclaimers and potential patent term adjustments.
- No active litigations or infringement suits are known as of 2023.
Development and Commercialization Landscape
- The patent underpins formulations like Pegasys (peginterferon alfa-2a) by Roche and PegIntron (peginterferon alfa-2b) by Merck.
- The intellectual property contributed substantially to the development of PEGylated interferons in treating hepatitis C and other viral diseases.
Key Overlapping and Differentiating Patents
- Patents US 6,630,382 and US 6,245,377 by Merck cover PEGylation processes and formulations similar to US 6,342,515.
- Differences lie in PEG size ranges, linkers, and conjugation chemistries.
Innovation and Patent Strategy
- The scope emphasizes PEG size and conjugation chemistry, which are critical for pharmacokinetics.
- Subsequent patents expanded claims to include other polymers, conjugation linkages, and therapeutic uses, creating a comprehensive patent landscape around PEGylation of interferons.
Risks and Opportunities
- The expiration of US 6,342,515 opens room for biosimilars targeting PEG-IFN formulations.
- Patent barriers persist in additional formulations and specific conjugation methods patented afterward.
- Ongoing R&D focuses on alternative conjugation chemistries, alternative polymers, and novel therapeutic uses.
Summary Table of Patent Claims and Landscape
| Aspect |
Scope/Details |
Status |
| Core composition |
PEG-IFN conjugates with PEG 20,000 Daltons |
Expired 2019 |
| Conjugation techniques |
Covalent linkage, ester/aldehyde chemistries |
Covered in multiple patents |
| Size and PEG variants |
10,000 to 40,000 Daltons, linear or branched |
Covered, broad variations |
| Therapeutic uses |
Antiviral, immunomodulation |
Focus of claims and subsequent patents |
Key Takeaways
- US 6,342,515 claims PEGylated interferon alpha compositions with specific PEG sizes and conjugation methods.
- The patent's expiration has opened market space for biosimilar development.
- The patent landscape includes related patents on PEG conjugation processes and alternate PEG sizes, linking to key treatments for hepatitis C.
- Strategic patenting around conjugation chemistries and PEG formulations continues, affecting biosimilar entry.
- The core claims remain relevant for understanding the technical scope of PEGylation in biologics.
FAQs
Q1: What is the primary invention claimed in US 6,342,515?
A: Conjugates of interferon alpha linked to PEG with a molecular weight of about 20,000 Daltons, aiming to improve pharmacokinetics.
Q2: How does the patent impact biosimilar development?
A: Its expiration allows biosimilar manufacturers to develop PEG-IFN products without infringing primary claims, provided they do not use protected conjugation chemistries.
Q3: Are there patents with broader or narrower claims related to US 6,342,515?
A: Yes. Broader patents cover PEG molecular weights from 10,000 to 40,000 Daltons, while narrower claims focus on specific conjugation chemistries.
Q4: What treatments use the technology described in this patent?
A: Mainly treatments for hepatitis C and multiple sclerosis, where PEGylated interferons are approved.
Q5: What are the key considerations for inventors designing next-generation PEGylated interferons?
A: Focus on alternative linkers, different PEG sizes, novel conjugation chemistries, and new therapeutic indications—areas where patent protection remains or is sought.
References
[1] USPTO. (2002). US Patent 6,342,515. Retrieved from https://patents.google.com/patent/US6342515
[2] Choi, H. K., et al. (2017). The evolution of PEGylation technology: From molecules to medicines. Trends in Pharmacological Sciences, 38(1), 37–49.
[3] Food and Drug Administration. (2022). Biologic approvals for PEGylated interferons.
More… ↓
⤷ Start Trial
|
